Interaction between CCAAT/enhancer binding protein and cyclic AMP response element binding protein 1 regulates human immunodeficiency virus type 1 transcription in cells of the monocyte/macrophage lineage
Recent observations have shown two CCAAT/enhancer binding protein (C/EBP) binding sites to be critically important for efficient human immunodeficiency virus type 1 (HIV-1) replication within cells of the monocyte/macrophage lineage, a cell type likely involved in transport of the virus to the brain. Additionally, sequence variation at C/EBP site I, which lies immediately upstream of the distal nuclear factor kappa B site and immediately downstream of a binding site for activating transcription factor (ATF)/cyclic AMP response element binding protein (CREB), has been shown to affect HIV-1 long terminal repeat (LTR) activity. Given that C/EBP proteins have been shown to interact with many other transcription factors including members of the ATF/CREB family, we proceeded to determine whether an adjacent ATF/CREB binding site could affect C/EBP protein binding to C/EBP site I. Electrophoretic mobility shift analyses indicated that selected ATF/CREB site variants assisted in the recruitment of C/EBP proteins to an adjacent, naturally occurring, low-affinity C/EBP site. This biophysical interaction appears to occur via at least two mechanisms. First, low amounts of CREB-1 and C/EBP appear to heterodimerize and bind to a site consisting of a half site from both the ATF/CREB and C/EBP binding sites. In addition, CREB-1 homodimers bind to the ATF/CREB site and recruit C/EBP dimers to their cognate weak binding sites. This interaction is reciprocal, since C/EBP dimer binding to a strong C/EBP site leads to enhanced CREB-1 recruitment to ATF/CREB sites that are weakly bound by CREB. Sequence variation at both C/EBP and ATF/CREB sites affects the molecular interactions involved in mediating both of these mechanisms. Most importantly, sequence variation at the ATF/CREB binding site affected basal LTR activity as well as LTR function following interleukin-6 stimulation, a treatment that leads to increases in C/EBP activation. Thus, HIV-1 LTR ATF/CREB binding site sequence variation may modulate cellular signaling at the viral promoter through the C/EBP pathway.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2001 |
---|---|
Erschienen: |
2001 |
Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
---|---|
Enthalten in: |
Journal of virology - 75(2001), 4 vom: Feb., Seite 1842-56 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ross, H L [VerfasserIn] |
---|
Themen: |
CCAAT-Enhancer-Binding Proteins |
---|
Anmerkungen: |
Date Completed 05.04.2001 Date Revised 13.11.2018 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM110740491 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM110740491 | ||
003 | DE-627 | ||
005 | 20231222154127.0 | ||
007 | tu | ||
008 | 231222s2001 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0370.xml |
035 | |a (DE-627)NLM110740491 | ||
035 | |a (NLM)11160683 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ross, H L |e verfasserin |4 aut | |
245 | 1 | 0 | |a Interaction between CCAAT/enhancer binding protein and cyclic AMP response element binding protein 1 regulates human immunodeficiency virus type 1 transcription in cells of the monocyte/macrophage lineage |
264 | 1 | |c 2001 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 05.04.2001 | ||
500 | |a Date Revised 13.11.2018 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Recent observations have shown two CCAAT/enhancer binding protein (C/EBP) binding sites to be critically important for efficient human immunodeficiency virus type 1 (HIV-1) replication within cells of the monocyte/macrophage lineage, a cell type likely involved in transport of the virus to the brain. Additionally, sequence variation at C/EBP site I, which lies immediately upstream of the distal nuclear factor kappa B site and immediately downstream of a binding site for activating transcription factor (ATF)/cyclic AMP response element binding protein (CREB), has been shown to affect HIV-1 long terminal repeat (LTR) activity. Given that C/EBP proteins have been shown to interact with many other transcription factors including members of the ATF/CREB family, we proceeded to determine whether an adjacent ATF/CREB binding site could affect C/EBP protein binding to C/EBP site I. Electrophoretic mobility shift analyses indicated that selected ATF/CREB site variants assisted in the recruitment of C/EBP proteins to an adjacent, naturally occurring, low-affinity C/EBP site. This biophysical interaction appears to occur via at least two mechanisms. First, low amounts of CREB-1 and C/EBP appear to heterodimerize and bind to a site consisting of a half site from both the ATF/CREB and C/EBP binding sites. In addition, CREB-1 homodimers bind to the ATF/CREB site and recruit C/EBP dimers to their cognate weak binding sites. This interaction is reciprocal, since C/EBP dimer binding to a strong C/EBP site leads to enhanced CREB-1 recruitment to ATF/CREB sites that are weakly bound by CREB. Sequence variation at both C/EBP and ATF/CREB sites affects the molecular interactions involved in mediating both of these mechanisms. Most importantly, sequence variation at the ATF/CREB binding site affected basal LTR activity as well as LTR function following interleukin-6 stimulation, a treatment that leads to increases in C/EBP activation. Thus, HIV-1 LTR ATF/CREB binding site sequence variation may modulate cellular signaling at the viral promoter through the C/EBP pathway | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
650 | 7 | |a CCAAT-Enhancer-Binding Proteins |2 NLM | |
650 | 7 | |a Cyclic AMP Response Element-Binding Protein |2 NLM | |
700 | 1 | |a Nonnemacher, M R |e verfasserin |4 aut | |
700 | 1 | |a Hogan, T H |e verfasserin |4 aut | |
700 | 1 | |a Quiterio, S J |e verfasserin |4 aut | |
700 | 1 | |a Henderson, A |e verfasserin |4 aut | |
700 | 1 | |a McAllister, J J |e verfasserin |4 aut | |
700 | 1 | |a Krebs, F C |e verfasserin |4 aut | |
700 | 1 | |a Wigdahl, B |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of virology |d 1967 |g 75(2001), 4 vom: Feb., Seite 1842-56 |w (DE-627)NLM000006866 |x 1098-5514 |7 nnns |
773 | 1 | 8 | |g volume:75 |g year:2001 |g number:4 |g month:02 |g pages:1842-56 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 75 |j 2001 |e 4 |c 02 |h 1842-56 |